The Basel pharmaceutical company, Novartis has agreed with the five health insurance Helsana, Sanitas, KPT, Swica, and CSS, as well as the exporting hospitals on a price for its new cell therapy Kymriah, which is aimed at the seriously ill cancer patients. The collective agreement regulates a level of remuneration "below the current list price of 370'755 CHF". This is evident from the design of a media message, which the "Sunday newspaper" exists. What is the exact price is, it does not say.
Kymriah is not a conventional cancer drug, but a treatment that is administered in the hospital once. In cancer patients, blood will be taken from the cells and then genetically modified in a way that you can fight the cancer cells. The converted blood the cells are then transplanted back into the patient. Kymriah will only be used stationary and in specially certified hospitals.
genetic engineering process
Kymriah was approved in Switzerland for the treatment of two types of cancer for certain blood cancers and Non-Hodgkin's lymphoma. The two indications are reimbursed in accordance with the agreement concluded varies. How high, have not disclosed the parties to the contract. The tiered pricing giving rise to the current data location and the number of affected patients.
the challenge for The actors in the Swiss health care system, have located that the new therapy is not a conventional drug, but a new genetic process associated with a single application, write to Novartis, the hospital Association of H-plus and the five funds. Consequently, it was regarded to regulate the issue of compensation. This was managed, refer to it as a "milestone". (Editorial Tamedia)
Created: 16.06.2019, 16:46 PM